Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Pembrolizumab in Early Stage Colon Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Ertugliflozin for Functional Mitral Regurgitation
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Longitudinal Immune-phenotyping of HCC Following MK-3475
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)
- Status
- COMPLETED
- Phase
- PHASE1
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab in Pre Neoplastic High Grade HPV-related Vulvar and Cervical Lesions
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4